A Study to Evaluate RL-007 in the Treatment of Cognitive Impairment Associated With Schizophrenia (CIAS)
Public ClinicalTrials.gov record NCT05686239. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Adaptive, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety and Efficacy of RL-007 in the Treatment of Cognitive Impairment Associated With Schizophrenia (CIAS)
Study identification
- NCT ID
- NCT05686239
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Recognify Life Sciences
- Industry
- Enrollment
- 242 participants
Conditions and interventions
Conditions
Interventions
- Placebo Drug
- RL-007 (Inidascamine) Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 55 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 7, 2022
- Primary completion
- Apr 8, 2025
- Completion
- Apr 8, 2025
- Last update posted
- Jul 29, 2025
2022 – 2025
United States locations
- U.S. sites
- 20
- U.S. states
- 10
- U.S. cities
- 20
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Recognify Research Site | Culver City | California | 90230 | — |
| Collaborative Neuroscience Research | Garden Grove | California | 92845 | — |
| Recognify Research Site | Lafayette | California | 94549 | — |
| Recognify Research Site | Oceanside | California | 92056 | — |
| Recognify Research Site | Orange | California | 92868 | — |
| Recognify Research Site | Torrance | California | 90502 | — |
| Recognify Research Site | Hialeah | Florida | 33016 | — |
| Recognify Research Site | Miami | Florida | 33135 | — |
| Recognify Research Site | Miami Lakes | Florida | 33016 | — |
| Recognify Research Site | Atlanta | Georgia | 30030 | — |
| Recognify Research Site | Augusta | Georgia | 30912 | — |
| Recognify Research Site | Gaithersburg | Maryland | 20877 | — |
| Recognify Research Site | Berlin | New Jersey | 08009 | — |
| Recognify Research Site | Brooklyn | New York | 11235 | — |
| Recognify Research Site | Chapel Hill | North Carolina | 27599 | — |
| Recognify Research Site | Cincinnati | Ohio | 45219 | — |
| Recognify Research Site | Cleveland | Ohio | 44122 | — |
| Recognify Research Site | Dallas | Texas | 75231 | — |
| Recognify Research Site | Houston | Texas | 77074 | — |
| Recognify Research Site | Everett | Washington | 98201 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 16 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05686239, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 29, 2025 · Synced May 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05686239 live on ClinicalTrials.gov.